Quarterly ResultAug 5, 2026, 04:24 PM
Adicet Bio Q2 Net Loss $21.4M; Prula-cel Update in 3Q/2026
AI Summary
Adicet Bio reported a net loss of $21.4 million, or $1.99 per share, for Q2 2026, an improvement from $31.2 million in Q2 2025. The company anticipates a comprehensive Phase 1 clinical update for prula-cel in LN/SLE in Q3 2026 and plans a regulatory filing for ADI-212 in mCRPC in Q3 2026. Additionally, Adicet Bio appointed Lloyd Klickstein as Interim Chief Medical Officer and expects its cash and investments of $118.2 million to fund operations into the second half of 2027.
Key Highlights
- Net loss for Q2 2026 was $21.4 million ($1.99/share), improved from $31.2 million in Q2 2025.
- R&D expenses decreased to $18.5 million in Q2 2026 from $28.4 million in Q2 2025.
- Cash, cash equivalents, and investments totaled $118.2 million as of June 30, 2026.
- Cash runway expected to fund operations into the second half of 2027.
- Phase 1 prula-cel clinical update for 22 LN/SLE patients anticipated in Q3 2026.
- Regulatory filing for ADI-212 in mCRPC expected in Q3 2026.
- Lloyd Klickstein, M.D., Ph.D. appointed Interim Chief Medical Officer.
Price Impact
More from ACET